印明柱：国家级青年人才

重庆大学附属三峡医院特聘教授，博士生导师

联系方式：yinmingzhu2008@126.com

教育经历：

2015.09-2018.06，耶鲁大学&中国药科大学联合培养 中西医结合基础专业（博士）；

2008.09-2011.06，哈尔滨医科大学 肿瘤学专业（硕士）；

2002.09-2008.06，哈尔滨医科大学 临床医学专业（俄语班）（本科）；

工作经历：

2024.05-至今，重庆大学附属三峡医院 研究员

2023.12-至今，重庆大学附属三峡医院 副院长、主任医师

2022.11-至今，重庆大学附属三峡医院特聘教授，博士生导师，肿瘤早期诊断中心、分子病理中心及临床研究中心主任、转化医学中心主任、中线（NUT）癌专科主任；

2020.08-至今，美国耶鲁大学医学院，病理科，兼职助理教授；

2020.12-2022.11，中南大学湘雅医院皮肤科副主任；

2018.03-2022.11，中南大学湘雅医院特聘教授、博士生导师，皮肤健康与疾病湖南省工程研究中心常务副主任；

2017.12-2018.03，美国耶鲁大学医学院，病理科，副研究员；

2012.11-2017.12，美国耶鲁大学医学院，病理科，博士后；

2011.11-2012.11，美国国立卫生研究院抗衰老研究所（NIH/NIA）遗传系博士后；

2014.08-2017.09，哈尔滨医科大学附属肿瘤医院，主治医师（期间国外联合培养学习）；

2011.07-2014.07, 哈尔滨医科大学附属肿瘤医院 临床医生（期间出国留学）。

人才荣誉：

2019年，国家高层次人才特殊支持计划青年拔尖人才称号；

2021年，湖南省杰出青年基金获得者；

2023年，工信部“领军人才”；

2023年，重庆英才A类称号；

2023年，首届重庆市医学领航人才称号；

2024年，重庆市卫生领域国家级后备人才。

获社会兼职：

2024.04-至今，中国抗癌协会肺癌整合防筛专委会 副主任委员；

2024.03-至今，中国食品药品企业质量安全促进会 常务理事（副会长）；

2023.12-2026.12，中国食品药品企业质量安全促进会数字医疗专业委员会 主任委员；

2023.09-至今，《中国新药与临床杂志》第12届编辑委员会委员；

2023.08-至今，国际类器官研究协会（International Society of Organoid Research）重要成员；

2023.07-2026.07，中国通信工业协会智能制造专家委员会 专家委员；

2023.02-2026.02，“一带一路”医疗器械监管科学上海理工大学研究院 客座教授；

2023.06-2026.06，中国抗癌协会肿瘤基因诊断专委会中线（NUT）癌基因诊断工作组组长；

2023.08-2026.04，中国食品药品企业质量安全促进会-细胞医药分会 副会长；

2023.05-2028.05，重庆市医药生物技术协会肿瘤临床试验专业委员会 副主任委员；

2022.12-至今，中国旅美科技协会总会 副会长兼重庆联络处主任；

2021年-2024年，中央党校公共经济研究会 课题组特约研究员；

2021年-至今，《Tumor Discovery》杂志创刊主编；

2023.12-至今，《MONOCYTOMICS》主编。

科研奖励：

2024年，获中国产学研合作创新奖（个人）一等奖，排1/1；

2024年，获中华医学科技奖一等奖（重要皮肤疾病代谢新特征发现与诊治新体系创建），排6/15；

2023年，获中国发明创业奖创新奖一等奖（基于AI技术的高精度药物设计与筛选平台的构建及应用），排1/6；

2023年，获湖南省博士后创新创业大赛[生物医药与现代农业赛道]银奖(教学成果奖）（基于主动寻靶的核酸适体探针在泛癌分子诊疗中的应用），排2/3；

2023年，获高等学校科学技术进步一等奖（皮肤肿瘤诊疗新体系建立与应用），排6/16；

2022年，获湖南省留学人员创业启动支持计划项目一等奖（创意组）（恶变循环肿瘤细胞（CTC）智能早诊机器人），排1/1；

2018年，获黑龙江省人民政府科技进步奖二等奖（基于代谢组学的妇科恶性肿瘤新辅助化疗敏感性和毒性反应的生物标志物提取和机理研究），排6/8。

发明专利：

1. 专利名称：宫颈癌患者使用紫杉醇和顺铂进行化疗敏感性预测方法。发明人：侯艳，印明柱，孙风宇，娄阁，李康。申请号：201510164414.2

2. 专利名称：杂环化合物及其盐、制备方法、用途和药物。发明人：印明柱，陈翔。专利号：ZL2018 1 1204859.9  授权号：CN109134448 B。（2020-11-27）

3. 专利名称：荧光酶抑制剂筛选模型建立方法及荧光酶抑制剂筛选方法。发明人：印明柱、曹东升、杨梓宜、陈翔。申请号：202010715628.5

4. 专利名称：分子靶标蛋白的筛选方法、装置、计算机设备和存储介质。发明人：印明柱、曹东升、杨素青、陈翔。申请号：202010716290.5

5. 专利名称：胶体筛选模型的构建方法和胶体筛选方法。发明人：曹东升、印明柱、陈翔、杨梓宜。申请号：202010818121.2

6. 专利名称：药物与靶点间的相互作用关系预测方法及装置。发明人：曹东升、印明柱、陈翔、杨素青、程岩。专利号：ZL 2020 1 0824226.9 授权号：CN 112133367 B。（2024-7-12）

7. 专利名称：诱导肝毒性预测方法、装置、计算机设备及存储介质。发明人：曹东升、印明柱、陈翔、付丽、刘璐。申请号：202010835987.4

8. 专利名称：药物副作用关系预测方法、系统、计算机设备和存储介质。发明人：曹东升、印明柱、陈翔、杨素青。专利号：ZL 2020 1 0837504.4授权号：CN 112071439 B。（2024-1-2）

9. 专利名称：细胞分类方法、装置、计算机设备和存储介质。发明人：印明柱、李轶群、陈翔。申请号：202010840988.8

10. 专利名称：原代肢端黑色素瘤细胞的培养方法及培养试剂盒。发明人：印明柱、胡睿、陈翔。专利号：ZL 2020 1 0705199.3 授权号：CN 113957052 B.（2023-8-1）

11. PCT专利名称：CD147-ANTIBODIES AND ANTI-CD147-CAR-T CELLS。发明人：陈翔、印明柱。申请号：119995-8033.US00

12. 专利名称：一种人细胞外基质金属蛋白酶诱导因子磁微粒化学发光免疫定量检测试剂盒及其检测方法。发明人：印明柱、陈翔。申请号：202210207499.8

13. 专利名称：5-硫-D-葡萄糖的合成方法。发明人：廖潇啸、印明柱、陈翔。申请号：202210336519.1

14. 专利名称：一种同时识别多种恶性肿瘤细胞的核酸适体及其应用。发明人：蒲颖、印明柱、陈翔。专利号：ZL 2022 1 0207946.X  授权号：CN 114507668 B.（2023-5-16）

15. 专利名称：循环肿瘤细胞检测方法、装置、设备及介质。发明人：印明柱,刘腾,胡春兰,李康,赖仁胜,吴粤松,张宗波。申请号：2024106174439

16. 专利名称：基于组学测序的皮肤黑色素痣良恶性预测方法. 发明人：李鑫,印明柱,潘旭,孙婕,张熹元,邓金海. 申请号：2024107346574

17. 专利名称：肺栓塞预测方法、装置、设备及介质. 发明人：邓金海,印明柱,刘丽珏,李鑫,潘腾,李亚明. 申请号：2024108772831

18. 专利名称：孕早期胎儿生物特征测量方法、装置、设备及介质. 发明人：邓金海,印明柱,刘丽珏,李鑫,潘腾,周宇涵. 申请号：2024108772901

软件著作：

1. 软件名称：集成对抗学习和图深度学习的空间组学空间域识别软件V1.0. 登记号：2024SR0139656. 著作权拥有者：刘腾;印明柱;于永翔. 2024-1-22

2. 软件名称：基于多级挖掘检测模型的循环肿瘤细胞检测软件 V1.0. 登记号：2024SR0137100. 著作权拥有者：刘腾;印明柱;赖仁胜;李康;薛柔. 2024-1-19.

3. 软件名称：基于几何深度学习的空间转录组精确聚类软件V1.0. 登记号：2023SR0890417. 著作权拥有者：刘腾; 印明柱. 2023-8-2.

4. 软件名称：基于软演员评论家算法的车辆决策控制软件 V1.0. 登记号：2023SR0889545. 著作权拥有者：刘腾; 印明柱.  2023-8-2.

5. 软件名称：一种基于深度增强学习的高速道路自动换道软件 V1.0. 登记号：2023SR0890437. 著作权拥有者：刘腾; 印明柱. 2023-8-2.

6. 软件名称：一种时空高斯混合变分自动编码器的空间转录组学综合分析软件 V1.0. 登记号：2023SR1534679. 著作权拥有者：刘腾; 印明柱. 2023-11-29.

7. 软件名称：基于多模态和多算法集成的综合分子靶标预测系统[简称：MetaTarFisher] V1.0. 登记号：2021SR0193852. 著作权拥有者：曹东升; 侯廷军; 印明柱; 陈翔; 董界. 2021-2-3.

8. 软件名称：基于多任务图神经网络的分子药代动力学性质和毒性在线预测平台[简称：ADMETIab] V2.0. 登记号：2021SR0278762. 著作权拥有者：曹东升；侯廷军；印明柱；陈翔. 2021-2-23.

9. 软件名称：数据驱动的分子警示子结构挖掘软件[简称：PySmash] V1.0. 登记号：2021SR0278764. 著作权人：曹东升；陈翔；侯廷军；印明柱；杨芷江. 2021-2-23.

       10.软件名称：频繁命中化合物(泛实验干扰化合物)在线预测平台[简称:ChemFH]V1.0. 登记号：2021SR0286222. 著作权拥有者：曹东升；侯廷军；印明柱；陈翔. 2021-2-24.

专家共识：

1. 中国抗癌协会肿瘤基因诊断专业委员会中线（NUT）癌基因诊断工作组，中国抗癌协会肿瘤标志专业委员会 . 中线（NUT）癌诊断与治疗专家共识（2023版）［J］. 中国癌症防治杂志，2023，15（5）：463⁃476. DOI：10.3969/j.issn.1674-5671.2023.05.01.（牵头撰写）

2. 中华医学会肿瘤学分会胃癌学组，中国医师协会结直肠肿瘤专业委员会，中国抗癌协会大肠癌专业委员会，中国抗癌协会胃癌专业委员会，中国抗癌协会消化道息肉及癌前病变专业委员会. 循环肿瘤细胞检测在胃肠道肿瘤诊疗中的应用中国专家共识（2023版）［J］. 中华胃肠外科杂志, 2023, 26(11)：1001-1007. DOI：10.3760/cma.j.cn441530-20230907-00080.

标准：

1. 鼠源单克隆抗体制备通用技术规程，T/CSBX 0005-2020，起草人：向双林、吴力军、付舒翔、田方艳、禹梁、朱淑英、刘伟、何伏明、周文婷、 李乐、杨丽霞、印明柱、李霞、刘杰锋、谢倩玉、左娅菲. 2020年.

课题基金：

成果转化:

讲授课程：

 著作：

发表文章：

（共发表SCI论文115篇，第一/通讯（含共同）58篇,Google学术H指数36；共发表中文核心期刊11篇）

2024年

[1] Yin M*#, Zhang Y#, Wang W#, Zhao S, Su J, Li S*, Chen X*. Identification of Two Molecularly and Prognostically Distinct Subtypes in Acral Melanoma Using Network Prediction Method. J Eur Acad Dermatol. 2024. (Accepted, Q1, 9.2)

[2] Dong L, Hu S, Li X, Pei S, Jin L, Zhang L, Chen X*, Min A*, Yin M*. SPP1+ TAM Regulates the Metastatic Colonization of CXCR4+ Metastasis-Associated Tumor Cells by Remodeling the Lymph Node Microenvironment. Adv Sci (Weinh). 2024 Sep 5:e2400524. （Q1, 15.1）

[3] Pan X#, Li X#, Dong L#, Liu T, Zhang M, Zhang L, Zhang X, Huang L, Shi W, Sun H, Fang Z, Sun J, Huang Y, Shao H, Wang Y, Yin M*. Tumour vasculature at single-cell resolution. Nature. 2024 Aug; 632(8024): 429-436.（Q1, 50.5）

[4] Jin L, Dong L, Pei S, Chen X, Kuang Y, Chen W, Zhu W*, Yin M*. A BET inhibitor, NHWD-870, can downregulate dendritic cells maturation via the IRF7-mediated signaling pathway to ameliorate imiquimod-induced psoriasis-like murine skin inflammation. Eur J Pharmacol. 2024 Feb 2:176382. doi: 10.1016/j.ejphar.2024.176382.  ( Q1, 5)

[5] Liu T, Ye J, Liao J, Yin M*. Artificial intelligence enabled spatially resolved transcriptomics reveal spatial tissue organization of multiple tumors, Tumor Discovery, 2024, 3(1): 2049.

[6] Liu T, Yang Y, Xiao W, Tang X, Yin M*. A Comparative Analysis of Deep Reinforcement Learning-enabled Freeway Decision-making for Automated Vehicles. IEEE Access, 2024, 12: 24090-24103. doi: 10.1109/ACCESS.2024.3358424.（Q2, 3.9）

[7] Chen M, Shan H, Tao Q, Hu R, Sun Q, Zheng M, Chen Z, Lin Q, Yin M*, Zhao S*, Chen X*, Chen Z*. Mimicking Tumor Metastasis Using a Transwell-Integrated Organoids-On-a-Chip Platform. Small. 2024 Feb 2: e2308525. doi: 10.1002/smll.202308525. （Q1, 13.3）

[8] Liu T, Fang Z, Li X, Zhang L, Cao DS, Li M*, Yin M*. Assembling spatial clustering framework for heterogeneous spatial transcriptomics data with GRAPHDeep. Bioinformatics. 2024 Jan 18:btae023. doi: 10.1093/bioinformatics/btae023. （Q1, 5.8）

[9] Hu R, Hou H, Li Y, Zhang M, Li X, Chen Y, Guo Y, Sun H, Zhao S, Liao M, Cao D, Yan Q*, Chen X*, Yin M*. Combined BET and MEK Inhibition synergistically suppresses melanoma by targeting YAP1. Theranostics. 2024 Jan 1; 14(2):593-607. doi:10.7150/thno.85437. （Q1, 12.4）

[10] Deng J, Pan T, Wang D, Hong Y, Liu Z, Zhou X, An Z, Li L, Alfano G, Li G, Dolcetti L, Evans R, Vicencio JM, Vlckova P, Chen Y, Monypenny J, Gomes CAC, Weitsman G, Ng K, McCarthy C, Yang X, Hu Z, Porter JC, Tape CJ, Yin M, Wei F, Rodriguez-Justo M, Zhang J, Tejpar S, Beatson R, Ng T. The MondoA-dependent TXNIP/GDF15 axis predicts oxaliplatin response in colorectal adenocarcinomas. EMBO Mol Med. 2024 Aug 5. doi: 10.1038/s44321-024-00105-2. （Q1, 9.0）

2023年

[11] Han Z, Hu H, Yin M, Lin Y, Yan Y, Han P, Liu B, Jing B*. HOXA1 participates in VSMC-to-macrophage-like cell transformation via regulation of NF-κB p65 and KLF4: a potential mechanism of atherosclerosis pathogenesis. Mol Med. 2023 Aug 1;29(1):104. doi: 10.1186/s10020-023-00685-8. （Q1，5.7）

[12] Fang Z#, Liu T#, Zheng R, A J, Yin M*, Li M*. stAA: adversarial graph autoencoder for spatial clustering task of spatially resolved transcriptomics. Brief Bioinform. 2023 Nov 22;25(1):bbad500. doi: 10.1093/bib/bbad500. (Q1, 13.994)

[13] Meng Y#, Sun HY#, He Y#, Zhou Q, Liu YH, Su H, Yin MZ, Zeng FR*, Chen X*, Deng GT*. BET inhibitors potentiate melanoma ferroptosis and immunotherapy through AKR1C2 inhibition. Mil Med Res. 2023 Dec 4;10(1):61. doi: 10.1186/s40779-023-00497-1. （Q1，21.1）

[14] Liu T, Fang ZY, Zhang Z, Yu Y, Li M*, Yin MZ*. A comprehensive overview of graph neural network-based approaches to clustering for spatial transcriptomics. Comput Struct Biotechnol J. 2023 Nov 30;23:106-128. doi: 10.1016/j.csbj.2023.11.055.  （Q2，6）

[15] Favre G, Gerbier E, Maisonneuve E, Pomar L, Winterfeld U, Lepigeon K, Bloemenkamp KWM, de Bruin O, Hurley E, Nordeng H, Siiskonen SJ, Sturkenboom MCJM, Baud D, Panchaud A; COVI-PREG and CONSIGN group (Mingzhu Yin). COVID-19-related medicine utilization study in pregnancy: The COVI-PREG cohort. Br J Clin Pharmacol. 2023 May; 89(5): 1560-1574. doi: 10.1111/bcp.15611. （Q2，3.4）

[16] Li Z, Wu X, Chen S, Zhong J, Qiu X, Kpegah JKSK, Shi K, Can L, Zhang X, Yin M, Xie H*, Su J*, Zhou J*. Identification of CRKL as an oncogenic biomarker for prognosis and immunotherapy in melanoma, and its potential molecular mechanism. Genomics. 2023 May; 115(3): 110634. doi: 10.1016/j.ygeno.2023.110634. （Q1，4.4）

[17] Han Z, Hu H, Yin M, Lin Y, Yan Y, Han P, Liu B, Jing B*. HOXA1 participates in VSMC-to-macrophage-like cell transformation via regulation of NF-κB p65 and KLF4: a potential mechanism of atherosclerosis pathogenesis. Mol Med. 2023 Aug 1;29(1):104. doi: 10.1186/s10020-023-00685-8. （Q2，5.7）

[18] Fang Z, Wang Y, Huang B*, Chen X*, Jiang R*, Yin M*. Depletion of G9A attenuates imiquimod-induced psoriatic dermatitis via targeting EDAR-NF-κB signaling in keratinocyte. Cell Death Dis. 2023 Sep 22; 14(9): 627. doi: 10.1038/s41419-023-06134-y. （Q1，9）

[19] Deng J, Pan T, Liu Z, McCarthy C, Vicencio JM, Cao L, Alfano G, Suwaidan AA, Yin M, Beatson R, Ng T. The role of TXNIP in cancer: a fine balance between redox, metabolic, and immunological tumor control. Br J Cancer. 2023 Oct 4. doi: 10.1038/s41416-023-02442-4. （Q1, 6.4）

[20] Fang Z, Sun H, Wang Y, Sun Z*, Yin M*. Discovery of WD-890: A novel allosteric TYK2 inhibitor for the treatment of multiple autoimmune diseases. Biomed Pharmacother. 2023 Nov; 167: 115611. doi: 10.1016/j.biopha.2023.115611. （Q1，7.5）

[21] Deng J#, Pan T#, Lv C, Cao L, Li L, Zhou X, Li G, Li H, Vicencio JM, Xu Y, Wei F, Wang Y, Liu Z*, Zhou G*, Yin M*.  Exosomal transfer leads to chemoresistance through oxidative phosphorylation-mediated stemness phenotype in colorectal cancer. Theranostics. 2023 Sep 11; 13(14): 5057-5074. doi: 10.7150/thno.84937.（Q1，12.4）

[22] Huang L, Wang X, Pei S, Li X, Dong L, Bian X, Sun H, Jin L, Hou H, Shi W, Zhang X, Zhang L, Zhao S, Chen X*, Yin M*. Single-Cell Profiling Reveals Sustained Immune Infiltration, Surveillance, and Tumor Heterogeneity in Infiltrative Basal Cell Carcinoma. J Invest Dermatol. 2023 May 17:S0022-202X(23)02066-3. doi: 10.1016/j.jid.2023.04.020. （Q1，6.5）

[23] Liu T, Fang ZY, Li X, Zhang LN, Cao DS*, Yin MZ*. Graph deep learning enabled spatial domains identification for spatial transcriptomics. Brief Bioinform. 2023 May 19, 24(3):bbad146. doi: 10.1093/bib/bbad146. （Q1，13.994）

[24] Guo Y, Jin L, Dong L, Zhang M, Kuang Y, Chen X*, Zhu W*, Yin M*. NHWD-1062 ameliorates inflammation and proliferation by the RIPK1/NF-κB/TLR1 axis in Psoriatic Keratinocytes. Biomed Pharmacother. 2023 Jun, 162: 114638. doi: 10.1016/j.biopha.2023.114638. （Q1，7.5）

[25] Hu R, Li Y, Guo Y, Li X, Du S, Liao M, Hou H, Sun H, Zhao S, Su J, Chen X*, Yin M*. BRD4 inhibitor suppresses melanoma metastasis via the SPINK6/EGFR-EphA2 pathway. Pharmacol Res. 2023 Jan, 187: 106609. doi: 10.1016/j.phrs.2022.106609. （Q1，10.334）

[26] Zeng F, Li Y, Meng Y, Sun H, He Y, Yin M*, Chen X*, Deng G*. BET inhibitors synergize with sunitinib in melanoma through GDF15 suppression. Exp Mol Med. 2023 Feb, 55(2): 364-376. doi: 10.1038/s12276-023-00936-y. （Q1，12.8）

[27] Li Z, Wu X, Chen S, Zhong J, Qiu X, Kpegah JKSK, Shi K, Can L, Zhang X, Yin M, Xie H, Su J, Zhou J. Identification of CRKL as an oncogenic biomarker for prognosis and immunotherapy in melanoma, and its potential molecular mechanism. Genomics. 2023, 115 (3): 110634. doi: 10.1016/j.ygeno.2023.110634. （Q1，4.4）

[28] Hongyin Sun, Kui Deng, Xingchen Zhou, Dongsheng Cao, Yan Cheng, Xiang Chen, Mingzhu Yin*. A novel gene prognostic signature lymphocyte cytosolic protein 2 regulates melanoma progression by activating tumor-infiltrating CD8+ T-cells through the interferon regulatory factor 5 signaling pathway. Tumor Discovery 2023, 2(1), 318. https://doi.org/10.36922/td.318.

     2022年

[29] Zhang M, Liu ZZ, Aoshima K, Cai WL, Sun H, Xu T, Zhang Y, An Y, Chen JF, Chan LH, Aoshima A, Lang SM, Tang Z, Che X, Li Y, Rutter SJ, Bossuyt V, Chen X, Morrow JS, Pusztai L, Rimm DL, Yin M*, Yan Q*. CECR2 drives breast cancer metastasis by promoting NF-κB signaling and macrophage-mediated immune suppression. Sci Transl Med. 2022 Feb 2, 14 (630): eabf5473. doi: 10.1126/scitranslmed.abf5473. （Q1,17.1）

[30] Du S, Zeng F, Sun H, Liu Y, Han P, Zhang B, Xue W, Deng G*, Yin M*, Cui B*. Prognostic and therapeutic significance of a novel ferroptosis related signature in colorectal cancer patients. BIOENGINEERED. 2022 Feb, 13 (2): 2498-2512. doi: 10.1080/21655979.2021.2017627. （Q1,6.832）

[31] Deng G, Zeng F, He Y, Meng Y, Sun H, Su J, Zhao S, Cheng Y, Chen X*, Yin M*. EEF2K silencing inhibits tumour progression through repressing SPP1 and synergizes with BET inhibitors in melanoma. Clin Transl Med. 2022 Feb, 12(2): e722. doi: 10.1002/ctm2.722. （Q1,10.6）

[32] Sun H, Huang B*, Cao J*, Yan Q*, Yin M*. Editorial: Epigenetic Regulation and Tumor Immunotherapy. Front Oncol. 2022 May 5, 12: 893157. doi: 10.3389/fonc.2022.893157. （Q2，5.738）

[33] Chen X, Wang K, Jiang S, Sun H, Che X, Zhang M, He J, Wen Y, Liao M, Li X, Zhou X, Song J, Ren X, Yi W, Yang J, Chen X, Yin M*, Cheng Y*. eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma. J Immunother Cancer. 2022 Mar, 10(3): e004026. doi: 10.1136/jitc-2021-004026. （Q1, 10.9）

[34] Peng C, Jian X, Xie Y, Li L, Ouyang J, Tang L, Zhang X, Su J, Zhao S, Liu H, Yin M, Wu D, Wan M, Xie L, Chen X. Genomic alterations of dermatofibrosarcoma protuberans revealed by whole-genome sequencing. Br J Dermatol. 2022, 186(6): 997-1009. doi: 10.1111/bjd.20976. （Q1, 11.113）

[35] Jiang R, Xu J, Zhang Y, Liu J, Wang Y, Chen M*, Chen X*, Yin M*. Ligustrazine alleviates psoriasis-like inflammation through inhibiting TRAF6/c-JUN/NFκB signaling pathway in keratinocyte. Biomed Pharmacother. 2022 Jun, 150: 113010. doi: 10.1016/j.biopha.2022.113010. （Q1, 7.5）

[36] Farshidfar F, Rhrissorrakrai K, Levovitz C, Peng C, Knight J, Bacchiocchi A, Su J, Yin M, Sznol M, Ariyan S, Clune J, Olino K, Parida L, Nikolaus J, Zhang M, Zhao S, Wang Y, Huang G, Wan M, Li X, Cao J, Yan Q, Chen X, Newman AM, Halaban R.Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis. Nat Commun. 2022,13(1): 898. doi: 10.1038/s41467-022-28566-4. （Q1, 17.694）

[37] Fu X , Yin M*.Monocytes in tumor:from the sight of Single-cell analysis.  Tumor Discovery. 2022, 1 (1): 1-19.

[38] Yin M. Editor's foreword to the inaugural issue of Tumor Discovery. Tumor Discovery. 2022, 1 (1): 1-3.

[39] Zhang X, Guo Y, Xiao T, Li J, Guo A, Lei L, Jin C, Long Q, Su J, Yin M, Liu H, Chen C, Zhou Z, Zhu S, Tao J, Hu S, Chen X, Peng C. CD147 mediates epidermal malignant transformation through the RSK2/AP-1 pathway. J Exp Clin Cancer Res, 2022, 41(1): 246. doi: 10.1186/s13046-022-02427-w. （Q1，12.658）

[40] Wang W, Liu X, Zhang Z, Yin M, Chen X, Zhao S, Wu L. Apigenin Induced Apoptosis by Downregulating Sulfiredoxin Expression in Cutaneous Squamous Cell Carcinoma. OXID MED CELL LONGEV. 2022, 2022: 8172866. doi: 10.1155/2022/8172866. （Q2,7.310）

[41] Xiao Y, Jing D, Tang Z, Peng C, Yin M, Liu H, Chen X, Shen M. Serum lipids and risk of incident psoriasis: a prospective cohort study from the UK Biobank study and Mendelian randomization analysis. J Invest Dermatol, 2022, 142(12): 3192-3199.e12. doi: 10.1016/j.jid.2022.06.015.（Q1，7.590）

[42] Zhang Y, Xia J, Zhang J, Mao J, Chen H, Lin H, Jiang P, He X, Xu X, Yin M*, Wang Z*. Validity of a Soft and Flexible 3D-Printed Nissen Fundoplication Model in Surgical Training. International Journal of Bioprinting, 2022 Mar 23, 8 (2): 546. doi: 10.18063/ijb.v8i2.546.（Q1，8.4）

[43] Li X, Zhao S, Bian X, Zhang L, Lu L, Pei S, Dong L, Shi W, Huang L, Zhang X, Chen M, Chen X*, Yin M*. Signatures of EMT, immunosuppression, and inflammation in primary and recurrent human cutaneous squamous cell carcinoma at single-cell resolution. Theranostics, 2022 Oct 31, 12(17): 7532-7549. doi: 10.7150/thno.77528.（Q1，12.4）

[44] Wu S, Li X, Shang L, Wu L, Li T, Li P, Ji Z, Hou J, Yin M*, Xu W*. The novel BRDT inhibitor NHWD870 shows potential as a male contraceptive in mice. Acta Biochim Biophys Sin (Shanghai). 2022, 54(12): 1789-1800. doi: 10.3724/abbs.2022135. （Q2，3.7）

2021年

[45] Pei S, Yuan X, Zhang Z, Yao R, Xie Y, Shen M, Li B*, Chen X*, Yin M*. Convalescent Plasma to Treat COVID-19: Clinical Experience and Efficacy. Aging (Albany NY). 2021 Mar 18, 13 (6): 7758-7766. doi: 10.18632/aging.202795. （Q2，5.955）

[46] Zhu S, Guo Y, Zhang X, Liu H, Yin M, Chen X, Peng C. Pyruvate kinase M2 (PKM2) in cancer and cancer therapeutics. Cancer Lett. 2021, 503: 240-248. doi: 10.1016/j.canlet.2020.11.018. （Q1，9.756）

[47] Vouga M, Favre G, Martinez-Perez O,......, Yin M, Haessig A, Ackermann S, Baud D, Panchaud A. Maternal outcomes and risk factors for COVID-19 severity among pregnant women. Sci Rep. 2021;11(1):13898. doi: 10.1038/s41598-021-92357-y.（Q2，4.996）

[48] Lu Y, Xiao Y, Yin MZ, Zhou XC, Wu LS, Chen WQ, Luo Y, Kuang YH, Zhu W. Polyethylene Glycol Ointment Alleviates Psoriasis-Like Inflammation Through Down-Regulating the Function of Th17 Cells and MDSCs. Front Med (Lausanne). 2021, 7: 560579. doi: 10.3389/fmed.2020.560579. （Q2，5.058）

[49] Dong L#, Pei S#, Ren Q, Fu S, Yu L, Chen H, Chen X*, Yin M*. Evaluation of vertical transmission of SARS-CoV-2 in utero: Nine pregnant women and their newborns. Placenta. 2021, 111: 91-96. doi: 10.1016/j.placenta.2021.06.007. （Q2，3.287）

[50] Fu L, Yang ZY, Yang ZJ, Yin MZ, Lu AP, Chen X, Liu S, Hou TJ, Cao DS. QSAR-assisted-MMPA to expand chemical transformation space for lead optimization. Brief Bioinform. 2021, 22(5): bbaa374. doi: 10.1093/bib/bbaa374.（Q1，13.994）

[51] Yang ZY, Dong J, Yang ZJ, Yin M, Jiang HL, Lu AP, Chen X, Hou TJ, Cao DS. ChemFLuo: a web-server for structure analysis and identification of fluorescent compounds. Brief Bioinform. 2021, 22(4): bbaa282. doi: 10.1093/bib/bbaa282.（Q1，13.994）

[52] Guo Y, Shen M, Zhang X, Xiao Y, Zhao S, Yin M, Bu W, Wang Y, Chen X, Su J. Unemployment and Health-Related Quality of Life in Melanoma Patients During the COVID-19 Pandemic. Front Public Health. 2021, 9: 630620. doi: 10.3389/fpubh.2021.630620. （Q1，6.461）

[53] Yang ZY, Yang ZJ, Zhao Y, Yin MZ, Lu AP, Chen X, Liu S, Hou TJ, Cao DS. PySmash: Python package and individual executable program for representative substructure generation and application. Brief Bioinform. 2021, 22(5): bbab017. doi: 10.1093/bib/bbab017. （Q1，13.994）

[54] Hu R, Zhao S, Su J, Chen X*, Yin M*. Establishment of cultured primary acral melanoma cells and animal models for Chinese patients. Pigment Cell Melanoma Res. 2021 Nov, 34 (6): 1131-1137. doi: 10.1111/pcmr.12996. （Q1，4.159）

[55] Xiong G, Wu Z, Yi J, Fu L, Yang Z, Hsieh C, Yin M, Zeng X, Wu C, Lu A, Chen X, Hou T, Cao D. ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Res. 2021, 49(W1): W5-W14. doi: 10.1093/nar/gkab255. （Q1，19.160）

[56] Jiang Y, Wang G, Mu H, Ma X, Wang Z, Lv Y, Zhang T, Xu J, Wang J, Li Y, Han J, Yang M, Wang Z, Zeng K, Jin X, Xue S, Yin M, Sun W, Hua Y, Cai Z. Bromodomain Inhibition Attenuates the Progression and Sensitizes the Chemosensitivity of Osteosarcoma by Repressing GP130/STAT3 Signaling. Front Oncol. 2021, 11: 642134. doi: 10.3389/fonc.2021.642134. （Q3,5.738）

[57] Liu N, Zhang J, Yin M, Liu H, Zhang X, Li J, Yan B, Guo Y, Zhou J, Tao J, Hu S, Chen X, Peng C. Inhibition of xCT suppresses the efficacy of anti-PD-1/L1 melanoma treatment through exosomal PD-L1-induced macrophage M2 polarization. Mol Ther. 2021, 29(7): 2321-2334. doi: 10.1016/j.ymthe.2021.03.013. （Q1，12.910）

[58] Zhang SM, Cai WL, Liu X, Thakral D, Luo J, Chan LH, McGeary MK, Song E, Blenman KRM, Micevic G, Jessel S, Zhang Y, Yin M, Booth CJ, Jilaveanu LB, Damsky W, Sznol M, Kluger HM, Iwasaki A, Bosenberg MW, Yan Q. KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements. NATURE. 2021, 598 (7882): 682-687. doi: 10.1038/s41586-021-03994-2. （Q1，69.504）

2020年

[59] Hu R, Han C, Pei S, Yin M*, Chen X*. Procalcitonin Levels in COVID-19 Patients. Int J Antimicrob Agents. 2020 Aug, 56(2):106051. doi: 10.1016/j.ijantimicag.2020.106051. （Q1，5.283）

[60] Jin L, Liu P, Yin M, Zhang M, Kuang Y, Zhu W. RIPK1: A rising star in inflammatory and neoplastic skin diseases. J Dermatol Sci. 2020, 99(3): 146-151. doi: 10.1016/j.jdermsci.2020.06.001. （Q1，4.563）

[61] Yin M*, Guo Y, Hu R, Cai WL, Li Y, Pei S, Sun H, Peng C, Li J, Ye R, Yang Q, Wang N, Tao Y, Chen X*, Yan Q*. Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction. Nat Commun. 2020 Apr 14, 11(1): 1833. doi: 10.1038/s41467-020-15290-0. （Q1，14.919）

[62] Liu N, Qi M, Li K, Zeng W, Li J, Yin M, Liu H, Chen X, Zhang J, Peng C. CD147 Regulates Melanoma Metastasis via the NFAT1-MMP-9 Pathway. Pigment Cell Melanoma Res. 2020, 33(5): 731-743. doi: 10.1111/pcmr.12886. （Q1，4.693）

[63] Zeng F, Huang Y, Guo Y, Yin M, Chen X, Xiao L, Deng G. Association of inflammatory markers with the severity of COVID-19: A meta-analysis. Int J Infect Dis. 2020, 96: 467-474. doi: 10.1016/j.ijid.2020.05.055. （Q2,3.623）

[64] Deng G, Zeng F*, Zhang L*, Chen H*, Chen X*, Yin M*. Characteristics of Pregnant COVID-19 Patients with Liver Injury. J Hepatol. 2020 Oct, 73(4): 989-991. doi: 10.1016/j.jhep.2020.06.022. （Q1，25.083）

[65] Li Z#, Yin M#, Zhang H, Ni W, Pierce RW, Zhou HJ, Min W. BMX Represses Thrombin-PAR1-Mediated Endothelial Permeability and Vascular Leakage During Early Sepsis. Circ Res. 2020 Feb 14, 126(4): 471-485. doi: 10.1161/CIRCRESAHA.119.315769. （Q1，17.367）

[66] Xue Y, Liu Y, Bian X, Zhang Y, Li Y*, Zhang Q*, Yin M*. miR-205-5p Inhibits Psoriasis-Associated Proliferation and Angiogenesis: Wnt/β-catenin and Mitogen-Activated Protein Kinase Signaling Pathway Are Involved. J Dermatol. 2020, 47(8): 882-892. doi: 10.1111/1346-8138.15370. （Q2,4.005）

[67] Chen XS, Wang KS, Guo W, Li LY, Yu P, Sun XY, Wang HY, Guan YD, Tao YG, Ding BN, Yin M, Ren XC, Zhang Y, Chen CS, Ye YC, Yang JM, Cheng Y. UCH-L1-mediated Down-regulation of Estrogen Receptor α Contributes to Insensitivity to Endocrine Therapy for Breast Cancer. Theranostics. 2020, 10(4): 1833-1848. doi: 10.7150/thno.39814. （Q1，11.556）

[68] Pei S, Xue Y, Zhao S, Alexander N, Mohamad G, Chen X*, Yin M*. Occupational Skin Conditions on the Front Line: A Survey Among 484 Chinese Healthcare Professionals Caring for Covid-19 Patients. J Eur Acad Dermatol Venereol. 2020 Aug, 34(8): e354-e357. doi: 10.1111/jdv.16570. （Q1，6.166）

[69] Li LY, Chen XS, Wang KS, Guan YD, Ren XC, Cao DS, Sun XY, Li AX, Tao YG, Zhang Y, Yin MZ, Wang XL, Wu MH, Yang JM, Cheng Y. RSK2 protects human breast cancer cells under endoplasmic reticulum stress through activating AMPKα2-mediated autophagy. Oncogene. 2020, 39(43): 6704-6718. doi: 10.1038/s41388-020-01447-0.（Q1，9.867）

[70] Liao M, Zeng F, Li Y, Gao Q, Yin M, Deng G, Chen X. A novel predictive model incorporating immune-related gene signatures for overall survival in melanoma patients. Sci Rep. 2020, 10(1): 12462. doi: 10.1038/s41598-020-69330-2. （Q3，4.379）

[71] Guo Y, Shen M, Zhang X, Xiao Y, Zhao S, Yin M, Bu W, Wang Y, Chen X, Su J. Association of Socioeconomic Changes due to the COVID-19 Pandemic With Health Outcomes in Patients With Skin Diseases: Cross-Sectional Survey Study. J Med Internet Res. 2020, 22(9): e22288. doi: 10.2196/22288. （Q2，5.428）

[72] Deng G#, Zeng F#, Su J, Zhao S, Hu R, Zhu W, Hu S, Chen X*, Yin M*. BET inhibitor suppresses melanoma progression via the noncanonical NF-κB/SPP1 pathway. Theranostics. 2020 Sep 15, 10(25): 11428-11443. doi: 10.7150/thno.47432. （Q1，11.556）

[73] Guan Y, Jiang S, Ye W, Ren X, Wang X, Zhang Y, Yin M, Wang K, Tao Y, Yang J, Cao D, Cheng Y. Combined treatment of mitoxantrone sensitizes breast cancer cells to rapalogs through blocking eEF-2K-mediated activation of Akt and autophagy. Cell Death Dis. 2020, 11(11): 948. doi: 10.1038/s41419-020-03153-x. （Q1，8.469）

[74] Yang SQ, Ye Q, Ding JJ, Yin MZ, Lu AP, Chen X, Hou TJ, Cao DS. Current advances in ligand-based target prediction. WIREs Comput Mol Sci. 2020, 1-21. doi: 10.1002/wcms.1504. （Q2, 25.113）

[75] Jin L, Liu P, Yin M, Zhang M, Kuang Y, Zhu W. RIPK1: A rising star in inflammatory and neoplastic skin diseases. J Dermatol Sci. 2020, 99(3): 146-151. doi: 10.1016/j.jdermsci.2020.06.001. （Q3，5.408）

[76] Deng G, Yin M, Chen X, Zeng F. Clinical determinants for fatality of 44,672 patients with COVID-19. Crit Care. 2020, 24(1): 179. doi: 10.1186/s13054-020-02902-w. （Q1，9.097）

[77] Liu P, Huang Z, Yin M, Liu C, Chen X, Pan P, Kuang Y. Safety and Efficacy of Ixekizumab and Antiviral Treatment for Patients with COVID-19: A structured summary of a study protocol for a Pilot Randomized Controlled Trial. Trials. 2020, 21(1): 999. doi: 10.1186/s13063-020-04925-8. （Q4, 2.279）

[78] Panchaud A, Favre G, Pomar L, Vouga M, Aebi-Popp K, Baud D; COVI-Preg group (Mingzhu Yin). An international registry for emergent pathogens and pregnancy. Lancet. 2020, 395(10235): 1483-1484. doi: 10.1016/S0140-6736(20)30981-8. （Q1，79.321）

[79] Ye Y, Kuang X, Xie Z, Liang L, Zhang Z, Zhang Y, Ma F, Gao Q, Chang R, Lee HH, Zhao S, Su J, Li H, Peng J, Chen H, Yin M, Peng C, Yang N, Wang J, Liu J, Liu H, Han L, Chen X. Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1. Genome Med. 2020, 12(1): 83. doi: 10.1186/s13073-020-00780-z. （Q1,11.117）

2019年

[80] Hu B, Hu H, Yin M*, Sun Z, Chen X, Li Y, Sun Z, Liu C, Li L, Qiu Y*. Sertad1 promotes prostate cancer progression through binding androgen receptor ligand binding domain. Int J Cancer. 2019 Feb 1,144(3): 558-568. doi: 10.1002/ijc.31877. （Q1,7.396）

[81] Yin M, Zhou HJ, Lin C, Long L, Yang X, Zhang H, Taylor H, Min W*. CD34+ KLF4+ Stromal Stem Cells Contribute to Endometrial Regeneration and Repair. Cell Rep. 2019 May 28, 27(9): 2709-2724.e3. doi: 10.1016/j.celrep.2019.04.088. （Q1,8.109）

2018年

[82] Li J, Yin M, Song W, Cui F, Wang W, Wang S, Zhu H. B Subunit of Human Chorionic Gonadotropin Promotes Tumor Invasion and Predicts Poor Prognosis of Early-Stage Colorectal Cancer. Cell Physiol Biochem. 2018, 45(1): 237-249. doi: 10.1159/000486770.

[83] Long L, Yin M, Min W. 3D Co-culture System of Tumor-associated Macrophages and Ovarian Cancer Cells. Bio Protoc. 2018 Apr 20, 8(8): e2815. doi: 10.21769/BioProtoc.2815.

[84] Han Z, Hu H, Yin M, Li X, Li J, Liu L, Liu B. miR-145 is critical for modulation of vascular smooth muscle cell proliferation in human carotid artery stenosis. J BIOL REG HOMEOS AG. 2018 May-Jun, 32 (3): 506-516. （Q4,1.558）

2017年

[85] Li L, Wei X, Wu B, Xiao Y, Yin M*, Yang Q*. siRNA-mediated knockdown of ID1 disrupts Nanog- and Oct-4-mediated cancer stem cell-likeness and resistance to chemotherapy in gastric cancer cells. ONCOL LETT. 2017, 13 (5): 3014-3024. doi: 10.3892/ol.2017.5828. （Q3，1.664）

[86] Zhang L, Fu Z, Li X, Tang H, Luo J, Zhang D, Zhuang Y, Han Z*, Yin M*. Transforming growth factor β-activated kinase 1 inhibitor suppresses the proliferation in triple-negative breast cancer through TGF-β/TGFR pathway. CHEM BIOL DRUG DES. 2017, 90 (3): 450-455. doi: 10.1111/cbdd.12965. （Q3，2.328）

[87] Yang K, Xia B, Wang W, Cheng J, Yin M, Xie, H, Li, J, Ma, L, Yang, C, Li, A, Fan, X, Dhillon, HS, Hou, Y, Lou, G, Li, K. A Comprehensive Analysis of Metabolomics and Transcriptomics in Cervical Cancer. Sci Rep. 2017, 7: 43353. doi: 10.1038/srep43353. （Q2，4.011）

[88] Tan S, Feng B, Yin M, Zhou HJ, Lou G, Ji W, Li Y, Min W. Stromal Senp1 promotes mouse early folliculogenesis by regulating BMP4 expression. Cell Biosci. 2017, 7: 36. doi: 10.1186/s13578-017-0163-5. （Q3，3.355）

[89] Yin M, Zhou HJ, Zhang J, Lin C, Li H, Li X, Li Y, Zhang H, Breckenridge DG, Ji W, Min W. ASK1-dependent endothelial cell activation is critical in ovarian cancer growth and metastasis. JCI Insight. 2017 Sep 21 , 2 (18): e91828. doi: 10.1172/jci.insight.91828. （Q1，6.014）

2016年

[90] Yin MZ#, Tan S#, Li X, Hou Y, Cao G, Li K, Kou J, Lou G. Identification of phosphatidylcholine and lysophosphatidylcholine as novel biomarkers for cervical cancers in a prospective cohort study. TUMOR BIOL. 2016, 37 (4): 5485-5492. doi: 10.1007/s13277-015-4164-x. （2.926）

[91] Cui CY, Sima J, Yin M, Michel M, Kunisada M, Schlessinger D. Identification of potassium and chloride channels in eccrine sweat glands. J Dermatol Sci. 2016, 81(2): 129-131. doi: 10.1016/j.jdermsci.2015.11.001. （Q3，3.675）

[92] Cao G, Ye X, Xu Y, Yin M, Chen H, Kou J, Yu B. YiQiFuMai powder injection ameliorates blood-brain barrier dysfunction and brain edema after focal cerebral ischemia-reperfusion injury in mice. Drug Des Devel Ther. 2016, 10: 315-325. doi: 10.2147/DDDT.S96818. （Q3，2.935）

[93] Huang B#, Yin M#, Li X, Cao G, Qi J, Lou G, Sheng S, Kou J, Chen K, Yu B. Migration-inducing gene 7 promotes tumorigenesis and angiogenesis and independently predicts poor prognosis of epithelial ovarian cancer. Oncotarget. 2016, 7(19): 27552-27566. doi: 10.18632/oncotarget.8487. （5.168）

[94] Fan L, Yin M, Ke C, Ge T, Zhang G, Zhang W, Zhou X, Lou G, Li K. Use of Plasma Metabolomics to Identify Diagnostic Biomarkers for Early Stage Epithelial Ovarian Cancer. J Cancer. 2016, 7 (10): 1265-1272. doi: 10.7150/jca.15074. （Q3，3.249）

[95] Zou S, Teixeira AM, Yin M, Xiang Y, Xavier-Ferrucio J, Zhang PX, Hwa J, Min W, Krause DS. Leukaemia-associated Rho guanine nucleotide exchange factor (LARG) plays an agonist specific role in platelet function through RhoA activation. Thromb Haemost. 2016,116(3): 506-516. doi: 10.1160/TH15-11-0848.  （Q2，4.952）

[96] Cao G, Jiang N, Hu Y, Zhang Y, Wang G, Yin M, Ma X, Zhou K, Qi J, Yu B, Kou J. Ruscogenin Attenuates Cerebral Ischemia-Induced Blood-Brain Barrier Dysfunction by Suppressing TXNIP/NLRP3 Inflammasome Activation and the MAPK Pathway. Int J Mol Sci. 2016, 17(9): 1418. doi: 10.3390/ijms17091418. （Q2，3.687）

[97] Yin M#, Li X#, Tan S#, Zhou HJ, Ji W, Bellone S, Xu X, Zhang H, Santin AD, Lou G, Min W. Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer. J Clin Invest. 2016 Nov 1, 126(11): 4157-4173. doi: 10.1172/JCI87252. （Q1，12.784）

2015年

[98] Ye Y#, Yin M#, Huang B, Wang Y, Li X, Lou G. CLIC1 a novel biomarker of intraperitoneal metastasis in serous epithelial ovarian cancer. Tumour Biol. 2015, 36(6): 4175-4179. doi: 10.1007/s13277-015-3052-8. （2.926）

[99] Ji W#, Li Y#, He Y#, Yin M#, Zhou HJ, Boggon TJ, Zhang H, Min W. AIP1 Expression in Tumor Niche Suppresses Tumor Progression and Metastasis. CANCER RES. 2015 Sep 1, 75 (17): 3492-3504. doi: 10.1158/0008-5472.CAN-15-0088. （Q1，8.556）

2014年

[100] Cui CY, Yin M, Sima J, Childress V, Michel M, Piao Y, Schlessinger D. Involvement of Wnt, Eda and Shh at defined stages of sweat gland development. Development. 2014, 141(19): 3752-60. doi: 10.1242/dev.109231. （Q2，6.059）

[101] Hou Y#, Yin M#, Sun F, Zhang T, Zhou X, Li H, Zheng J, Chen X, Li C, Ning X, Lou G, Li K. A metabolomics approach for predicting the response to neoadjuvant chemotherapy in cervical cancer patients. Mol Biosyst. 2014, 10(8): 2126-33. doi: 10.1039/c4mb00054d. （2.829）

[102] Ge T, Yin M, Yang M, Liu T, Lou G. MicroRNA-302b suppresses human epithelial ovarian cancer cell growth by targeting RUNX1. Cell Physiol Biochem. 2014, 34(6): 2209-2220. doi: 10.1159/000369664. （4.652）

2013年

[103] Zhang T, Wu X, Ke C, Yin M, Li Z, Fan L, Zhang W, Zhang H, Zhao F, Zhou X, Lou G, Li K. Identification of potential biomarkers for ovarian cancer by urinary metabolomic profiling. J Proteome Res. 2013, 12(1): 505-512. doi: 10.1021/pr3009572. （Q2，4.173）

[104] Yin M#, Hou Y#, Zhang T, Cui C, Zhou X, Sun F, Li H, Li X, Zheng J, Chen X, Li C, Ning X, Li K, Lou G. Evaluation of chemotherapy response with serum squamous cell carcinoma antigen level in cervical cancer patients: a prospective cohort study. PLoS One. 2013, 8(1): e54969. doi: 10.1371/journal.pone.0054969. （Q3，3.057）

2012年

[105] Yin M, Lou C, Zhang W, Meng F, Zhang H, Ning X, Zhou R, Dong X, Lou G. LAPTM4B overexpression is a novel independent prognostic marker for metastatic ovarian tumors. Int J Gynecol Cancer. 2012 Jan;22(1):54-62. doi: 10.1097/IGC.0b013e318234f9ac. （Q3, 4.8）

[106] Zhang T, Wu X, Yin M, Fan L, Zhang H, Zhao F, Zhang W, Ke C, Zhang G, Hou Y, Zhou X, Lou G, Li K. Discrimination between malignant and benign ovarian tumors by plasma metabolomic profiling using ultra performance liquid chromatography/mass spectrometry. Clin Chim Acta. 2012 May 18;413(9-10):861-8. doi: 10.1016/j.cca.2012.01.026.

[107] Fan L, Zhang W, Yin M, Zhang T, Wu X, Zhang H, Sun M, Li Z, Hou Y, Zhou X, Lou G, Li K. Identification of metabolic biomarkers to diagnose epithelial ovarian cancer using a UPLC/QTOF/MS platform. Acta Oncol. 2012 Apr; 51(4): 473-9. doi: 10.3109/0284186X.2011.648338.

[108] Kang Y, Yin M, Jiang W, Zhang H, Xia B, Xue Y, Huang Y. Overexpression of LAPTM4B-35 is associated with poor prognosis in colorectal carcinoma. Am J Surg. 2012 Nov;204(5):677-83. doi: 10.1016/j.amjsurg.2012.02.003.

[109] Yin M, Zhang H, Li H, Li X, Liu Y, Chen X, Lou G, Li K. The toxicity and long-term efficacy of nedaplatin and paclitaxel treatment as neoadjuvant chemotherapy for locally advanced cervical cancer. J Surg Oncol. 2012 Feb;105(2):206-11. doi: 10.1002/jso.22052. （Q3,3.151）

2011年

[110] Meng F, Song H, Luo C, Yin M, Xu Y, Liu H, Zhou R, Lou G. Correlation of LAPTM4B polymorphisms with cervical carcinoma. Cancer. 2011 Jun 15;117(12):2652-8. doi: 10.1002/cncr.25833.

[111] Yin M, Li C, Li X, Lou G, Miao B, Liu X, Meng F, Zhang H, Chen X, Sun M, Ling Q, Zhou R. Over-expression of LAPTM4B is associated with poor prognosis and chemotherapy resistance in stages III and IV epithelial ovarian cancer. J Surg Oncol. 2011 Jul 1;104(1):29-36. doi: 10.1002/jso.21912. （Q3,3.151）

[112] Yin M, Zhao F, Lou G, Zhang H, Sun M, Li C, Hou Y, Li X, Meng F, Chen X. The long-term efficacy of neoadjuvant chemotherapy followed by radical hysterectomy compared with radical surgery alone or concurrent chemoradiotherapy on locally advanced-stage cervical cancer. Int J Gynecol Cancer. 2011 Jan;21(1):92-9. doi: 10.1111/IGC.0b013e3181fe8b6e.

[113] Yin M, Xu Y, Lou G, Hou Y, Meng F, Zhang H, Li C, Zhou R. LAPTM4B overexpression is a novel predictor of epithelial ovarian carcinoma metastasis. Int J Cancer. 2011 Aug 1;129(3):629-35. doi: 10.1002/ijc.25689. （Q3,4.8）

2010年

[114] Meng F, Luo C, Hu Y, Yin M, Lin M, Lou G, Zhou R. Overexpression of LAPTM4B-35 in cervical carcinoma: a clinicopathologic study. Int J Gynecol Pathol. 2010 Nov;29(6):587-93. doi: 10.1097/PGP.0b013e3181e0898e.  

[115] Meng FL, Yin MZ, Song HT, Yang H, Lou G, Zhou RL. LAPTM4B-35 overexpression is an independent prognostic marker in endometrial carcinoma. Int J Gynecol Cancer. 2010 Jul;20(5):745-50. doi: 10.1111/IGC.0b013e3181e02f90.

共发表中文论文11篇

[1] 刘 腾, 李 鑫, 印明柱*. 基于变分自编码器的空间转录组细胞聚类研究[J]. 生物信息学, 2023,21(4):247-269. DOI:10.12113/202305003

[2] 卞小慧,印明柱*. EDA在少汗性外胚层发育不良的发病机制及Fc-EDA的治疗作用[J].皮肤科学通报, 2020, 37(1): 5. DOI: CNKI:SUN:ZYXW.0.2020-01-008.

[3] 杨巧红,张新江,杜清,李琳琳,蓝华全,吕依扬,黄舒蕾,印明柱*,魏小勇*. 胃癌靶向治疗机制及 中西医药物治疗情况的研究进展[J].转化医学电子杂志, 2018, 5(9): 9. DOI: CNKI:SUN:ZHDZ.0.2018-09-008.

[4] 夏百荣,印明柱,葛婷婷,卢北燕*,娄阁. Hepsin在卵巢上皮癌组织中的表达及其与预后的关系[J].中国妇产科临床杂志, 2013. DOI: CNKI:SUN:FKLC.0.2013-02-017.

[5] 印明柱,娄阁*,孙喜文. 血清蛋白指纹图谱检测在卵巢癌中应用研究进展[J].实用肿瘤学杂志, 2013, 27(002): 177-180. DOI: 10.3969/j.issn.1002-3070.2013.02.019.

[6] 陈秀玮,王丹云,刘佳,印明柱,娄阁,高颖,康熙熊,张广美*. 白桦脂酸对HeLa细胞的抑制作用及其机制研究[J].中国癌症杂志, 2012, 22(4): 5. DOI: 10.3969/j.issn.1007-3639.2012.04.003.

[7]印明柱,娄阁*,陈秀玮,顾泰华. 新辅助化疗后根治性手术与同步放化疗在局部晚期宫颈癌的远期疗效评价[J].实用肿瘤学杂志, 2011, 25(1): 6. DOI: 10.3969/j.issn.1002-3070.2011.01.012.

[8] 王丹云,刘佳,印明柱,李雪婷,娄阁,刘运铎,陈秀玮*. 白桦酯醇诱导宫颈癌HeLa细胞凋亡及作用机制的研究[J].肿瘤, 2012, 32(4): 5. DOI:10.3781/j.issn.1109-0721.2012.04.002.

[9]印明柱,刘伟,娄阁,夏百荣. 孕产期合并Krukenberg瘤一例报道[J].实用肿瘤学杂志, 2011, 25(3): 2. DOI: 10.3969/j.issn.1002-3070.2011.03.015.

[10] 刘珺珺,印明柱,李聪,娄阁. 阿米福汀联合腹腔灌注化疗治疗难治性及复发性卵巢癌疗效观察[J].亚太传统医药, 2011, 7(10): 3. DOI: CNKI:SUN:YTCT.0.2011-10-051.

[11]印明柱,娄阁.新基因LAPTM4B与肿瘤[J].国际肿瘤学杂志, 2011, 38(1): 3. DOI: 10.3760/cma.j.issn.1673-422X.2011.01.004.